177 related articles for article (PubMed ID: 31374006)
21. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.
Thornton K; Kim G; Maher VE; Chattopadhyay S; Tang S; Moon YJ; Song P; Marathe A; Balakrishnan S; Zhu H; Garnett C; Liu Q; Booth B; Gehrke B; Dorsam R; Verbois L; Ghosh D; Wilson W; Duan J; Sarker H; Miksinski SP; Skarupa L; Ibrahim A; Justice R; Murgo A; Pazdur R
Clin Cancer Res; 2012 Jul; 18(14):3722-30. PubMed ID: 22665903
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW
Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385
[TBL] [Abstract][Full Text] [Related]
23. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Wells SA; Robinson BG; Gagel RF; Dralle H; Fagin JA; Santoro M; Baudin E; Elisei R; Jarzab B; Vasselli JR; Read J; Langmuir P; Ryan AJ; Schlumberger MJ
J Clin Oncol; 2012 Jan; 30(2):134-41. PubMed ID: 22025146
[TBL] [Abstract][Full Text] [Related]
24. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Leboulleux S; Bastholt L; Krause T; de la Fouchardiere C; Tennvall J; Awada A; Gómez JM; Bonichon F; Leenhardt L; Soufflet C; Licour M; Schlumberger MJ
Lancet Oncol; 2012 Sep; 13(9):897-905. PubMed ID: 22898678
[TBL] [Abstract][Full Text] [Related]
25. Vandetanib: in medullary thyroid cancer.
Frampton JE
Drugs; 2012 Jul; 72(10):1423-36. PubMed ID: 22715896
[TBL] [Abstract][Full Text] [Related]
26. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
Kim M; Yoon JH; Ahn J; Jeon MJ; Kim HK; Lim DJ; Kang HC; Kim IJ; Shong YK; Kim TY; Kim BH
Endocrinol Metab (Seoul); 2020 Sep; 35(3):587-594. PubMed ID: 32981301
[TBL] [Abstract][Full Text] [Related]
27. Vandetanib therapy in medullary thyroid cancer.
Grabowski P; Briest F; Baum RP; Zaknun JJ; Kulkarni HR; Zeitz M; Hörsch D
Drugs Today (Barc); 2012 Nov; 48(11):723-33. PubMed ID: 23170308
[TBL] [Abstract][Full Text] [Related]
28. Vandetanib: first global approval.
Commander H; Whiteside G; Perry C
Drugs; 2011 Jul; 71(10):1355-65. PubMed ID: 21770481
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma: single center result from a phase Ⅲ study].
Wang SX; Zhang XW; Wang XX; An CM; Zhang YB; Liu W; Zhao YF; He XH; Li ZJ; Niu LJ; Tang PZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jun; 54(6):439-444. PubMed ID: 31262109
[No Abstract] [Full Text] [Related]
31. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.
Hu MI; Elisei R; Dedecjus M; Popovtzer A; Druce M; Kapiteijn E; Pacini F; Locati L; Krajewska J; Weiss R; Gagel RF
Endocr Relat Cancer; 2019 Feb; 26(2):241-250. PubMed ID: 30557850
[TBL] [Abstract][Full Text] [Related]
32. Vandetanib: a guide to its use in advanced medullary thyroid cancer.
Keating GM; Lyseng-Williamson KA; Frampton JE
BioDrugs; 2012 Dec; 26(6):431-5. PubMed ID: 22938056
[TBL] [Abstract][Full Text] [Related]
33. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic hotline. A rare vandetanib-induced photo-allergic drug eruption.
Fava P; Quaglino P; Fierro MT; Novelli M; Bernengo MG
Dermatol Ther; 2010; 23(5):553-5. PubMed ID: 20868411
[TBL] [Abstract][Full Text] [Related]
35. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.
Massicotte MH; Borget I; Broutin S; Baracos VE; Leboulleux S; Baudin E; Paci A; Deroussent A; Schlumberger M; Antoun S
J Clin Endocrinol Metab; 2013 Jun; 98(6):2401-8. PubMed ID: 23543666
[TBL] [Abstract][Full Text] [Related]
36. Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.
Goldstein J; Patel AB; Curry JL; Subbiah V; Piha-Paul S
BMC Dermatol; 2015 Feb; 15():2. PubMed ID: 25886034
[TBL] [Abstract][Full Text] [Related]
37. Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib.
Pilco Teran M; Merino Ribas A; Martin Alemany N; Barros Freiria X; Rubio Casadevall J; Pérez Bueno F; García Méndez I; Castillo Devia M; Noboa Paez C; Torguet Escuder P; Calabia Martínez J
Invest New Drugs; 2021 Feb; 39(1):237-239. PubMed ID: 32648118
[TBL] [Abstract][Full Text] [Related]
38. Vandetanib: too dangerous in medullary thyroid cancer.
Prescrire Int; 2012 Oct; 21(131):233. PubMed ID: 23185843
[TBL] [Abstract][Full Text] [Related]
39. Vandetanib for the treatment of thyroid cancer.
Langmuir PB; Yver A
Clin Pharmacol Ther; 2012 Jan; 91(1):71-80. PubMed ID: 22158569
[TBL] [Abstract][Full Text] [Related]
40. Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis.
Scheffel RS; Dora JM; Siqueira DR; Burttet LM; Cerski MR; Maia AL
Eur J Endocrinol; 2013 Jun; 168(6):K51-4. PubMed ID: 23487538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
